688222.SHG HitGen Inc. A
- Market cap
- CNY 14.3B
- P/E
- 86.9x
- P/B
- 8.47x
- ROE
- 11.7%
- Dividend yield
- 0.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688222.SHG undervalued?
Graham numberThe Graham number of HitGen Inc. A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HitGen Inc. A fundamental analysis
No fundamental analysis for HitGen Inc. A yet.
HitGen Inc. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HitGen Inc. A
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which …
Full company profileHitGen Inc. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HitGen Inc. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 264M | 244M | 311M | 330M | 371M | 427M | 526M | 733M |
| Gross Profit | 215M | 193M | 146M | 157M | 183M | 221M | 285M | 428M |
| Operating Income | 124M | 62.4M | 35.2M | -5.01M | 34.3M | 86.6M | 133M | 250M |
| EBITDA | 147M | 83.2M | 108M | 66.6M | 93.8M | 122M | 180M | 209M |
| Net Income | 120M | 64.0M | 63.4M | 25.3M | 40.7M | 51.4M | 110M | 186M |
| EPS | 0.33 | 0.16 | 0.16 | 0.06 | 0.10 | 0.13 | 0.27 | 0.46 |
| Balance Sheet | ||||||||
| Total Assets | 635M | 1.69B | 1.71B | 1.67B | 1.73B | 1.76B | 1.95B | 2.24B |
| Total Liabilities | 124M | 407M | 398M | 342M | 347M | 334M | 447M | 644M |
| Shareholders' Equity | 512M | 1.28B | 1.32B | 1.30B | 1.36B | 1.39B | 1.50B | 1.59B |
| Cash & Short-term Investments | 334M | 430M | 374M | 358M | 377M | 462M | 624M | 818M |
| Cash Flow | ||||||||
| Operating Cash Flow | 168M | 1.59M | 43.5M | 52.7M | 125M | 128M | 216M | - |
| Capital Expenditure | 61.3M | 82.7M | 140M | 87.3M | 53.7M | 71.7M | 161M | 153M |
| Free Cash Flow | 107M | -81.1M | -96.4M | -34.6M | 71.5M | 56.3M | 55.8M | 87.5M |
| Ratios | ||||||||
| ROE | 23.5% | 5.0% | 4.8% | 1.9% | 3.0% | 3.7% | 7.3% | 11.7% |
| ROA | 18.9% | 3.8% | 3.7% | 1.5% | 2.4% | 2.9% | 5.6% | 8.3% |
| Net Profit Margin | 45.5% | 26.3% | 20.4% | 7.7% | 11.0% | 12.0% | 20.8% | 25.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HitGen Inc. A dividends
- Dividend yield
- 0.24%
- Forward dividend
- 0.13 CNY
- Payout ratio
- 31.1%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 34.0M | 0.08 | 31.1% |
| 2024 | CNY 31.3M | 0.08 | 60.9% |
| 2023 | CNY 11.0M | 0.03 | 27.1% |
| 2022 | CNY 27.6M | 0.07 | 109.2% |
| 2021 | CNY 23.6M | 0.06 | 37.2% |
| 2020 | CNY 50.3M | 0.13 | 78.5% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns HitGen Inc. A
- Insiders 45.63%
- Institutions 5.49%
- Public & others 48.89%
- Shares outstanding 401M
- Free float 209M
HitGen Inc. A company profile
- Company name
- HitGen Inc. A
- Ticker
- 688222.SHG
- ISIN
- CNE1000040G3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 546
- Fiscal year end
- December
- Address
- Building C2, Chengdu, China, 610200
- Phone
- 86 28 8519 7385
- Website
- hitgen.com
About HitGen Inc. A
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.
HitGen Inc. A management
7- Dr. Li JinChairman, GM & CEO · born 1963
- Dr. Hongge Liu CFA, Ph.D.Chief Financial Officer · born 1970
- Dr. Guansai LiuSenior Vice President · born 1982
- Mr. Shiwei GengSecretary · born 1987
- Dr. Dengfeng DouDeputy General Manager · born 1975
- Ms. Chunyan HuAccounting Supervisor · born 1975
- Mr. Barry A. MorganChief Scientist · born 1947